AccessPak for HIV PEP Basic Alternatives Compared
AccessPak for HIV PEP Basic | Bictegravir / emtricitabine / tenofovir alafenamide | Emtricitabine / tenofovir alafenamide |
|
---|
AccessPak for HIV PEP Basic (emtricitabine / tenofovir) | Bictegravir / emtricitabine / tenofovir alafenamide | Emtricitabine / tenofovir alafenamide |
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Pre-Exposure Prophylaxis, HIV Infection, Occupational Exposure, Nonoccupational Exposure. AccessPak for HIV PEP Basic may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for HIV Infection. bictegravir / emtricitabine / tenofovir alafenamide may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Pre-Exposure Prophylaxis, HIV Infection. emtricitabine / tenofovir alafenamide may also be used for purposes not listed in this medication guide. |
||||||||
More about AccessPak for HIV PEP Basic (emtricitabine / tenofovir) | More about Bictegravir / emtricitabine / tenofovir alafenamide | More about Emtricitabine / tenofovir alafenamide | ||||||||
Ratings & Reviews | ||||||||||
AccessPak for HIV PEP Basic has an average rating of 1.0 out of 10 from a total of 1 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 100% reported a negative effect. |
Bictegravir / emtricitabine / tenofovir alafenamide has an average rating of 7.2 out of 10 from a total of 211 ratings on Drugs.com. 58% of reviewers reported a positive effect, while 20% reported a negative effect. |
Emtricitabine / tenofovir alafenamide has an average rating of 6.9 out of 10 from a total of 16 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 27% reported a negative effect. |
||||||||
Drug Class | ||||||||||
Side Effects | ||||||||||
See also: AccessPak for HIV PEP Basic side effects in more detail. |
See also: bictegravir / emtricitabine / tenofovir alafenamide side effects in more detail. |
See also: emtricitabine / tenofovir alafenamide side effects in more detail. |
||||||||
Generic Availability | ||||||||||
Lower cost generic approved |
N/A |
Lower cost generic |
||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
||||||||
Dosage Forms Available | ||||||||||
N/A |
N/A |
|
||||||||
Brand Names | ||||||||||
Other emtricitabine / tenofovir brands include: Truvada | Biktarvy | Descovy | ||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
25.7 hours |
180 hours |
25.7 hours |
||||||||
CSA Schedule ** View glossary of terms | ||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | ||||||||||
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
Drug Interactions | ||||||||||
A total of 238 drugs are known to interact with AccessPak for HIV PEP Basic:
|
A total of 427 drugs are known to interact with bictegravir / emtricitabine / tenofovir alafenamide:
|
A total of 238 drugs are known to interact with emtricitabine / tenofovir alafenamide:
|
||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
Disease Interactions | ||||||||||
First Approval Date | ||||||||||
N/A |
February 07, 2018 |
April 04, 2016 |
||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||
N/A |
N/A |
N/A |
||||||||
More Information | ||||||||||
Patient resources | ||||||||||
Professional Resources | ||||||||||
N/A |
||||||||||
Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.